|
| Press Releases |
|
 |
|
| Friday, April 12, 2024 |
|
|
雲頂新耀耐賦康(R)，引領IgA腎病治療新時代 |
| 近日，Vertex Pharmaceuticals公佈以49億美元現金收購Alpine Immune Science，在目前的市場環境下，該筆巨額收購交易引起極高的市場關注，再次凸顯了腎科領域，尤其是IgA腎病賽道的巨大潛力。 more info >> |
|
| Monday, March 18, 2024 |
|
|
云顶新耀：创新药企低谷中的增长秘诀 |
2021年，国内创新药板块整体进入了下行通道，市场预期不断走低。但不论市场如何悲观，行业向前发展的基本原则不会变。部分极具战略前瞻性的biotech，已率先走出低谷。
more info >> |
|
|
雲頂新耀：創新藥企低谷中的增長秘訣 |
2021年，國內創新藥板塊整體進入了下行通道，市場預期不斷走低。但不論市場如何悲觀，行業向前發展的基本原則不會變。部分極具戰略前瞻性的biotech，已率先走出低谷。
more info >> |
|
| Saturday, March 16, 2024 |
|
|
云顶新耀：双轮驱动，“蓝海”争先，进入全新发展阶段 |
| 在当前整体经济和行业发展面临的挑战下，医药行业的竞争愈发激烈。特别是在曾被视为黄金路径的领域，如ADC（抗体药物偶联物）和PD-1抑制剂等，竞争已经过于拥挤。 more info >> |
|
|
雲頂新耀：雙輪驅動，「藍海」爭先，進入全新發展階段 |
| 在當前整體經濟和行業發展面臨的挑戰下，醫藥行業的競爭愈發激烈。特別是在曾被視為黃金路徑的領域，如ADC（抗體藥物偶聯物）和PD-1抑制劑等，競爭已經過於擁擠。 more info >> |
|
| Friday, October 25, 2024 |
|
|
Everest Medicines Announces the Launch of VELSIPITY(R) in the Guangdong-Hong Kong-Macau Greater Bay Area |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that, through the "Hong Kong and Macau Medicine and Equipment Connect" policy, VELSIPITY(R) has officially been approved for patients with moderately to severely active ulcerative colitis (UC) by the Guangdong Provincial Medical Products Administration and can first be used in the Foshan Fosun Chancheng Hospital and the First Affiliated Hospital of Sun Yat-sen University, two of the medical institutions designated by the "Hong Kong and Macau Medicine and Equipment Connect" policy in the Greater Bay Area. more info >> |
|
|
云顶新耀宣布伊曲莫德（VELSIPITY）获批进入粤港澳大湾区 为溃疡性结肠炎患者带来新选择 |
| 云顶新耀（HKEX 1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布，得益于“港澳药械通”政策，伊曲莫德（VELSIPITY®）正式获得“粤港澳大湾区内地临床急需进口港澳药品批件”批准，可以在佛山复星禅诚医院、中山大学附属第一医院两家大湾区药械通政策指定的医疗机构先行使用，后续该产品将在其他药械通资质医院陆续引入。 more info >> |
|
|
雲頂新耀宣佈伊曲莫德（VELSIPITY(R)）獲批進入粵港澳大灣區 為潰瘍性結腸炎患者帶來新選擇 |
| 雲頂新耀（HKEX 1952.HK）是一家專注于創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈，得益於「港澳藥械通」政策，伊曲莫德（VELSIPITY(R)）正式獲得「粵港澳大灣區內地臨床急需進口港澳藥品批件」批准，可以在佛山複星禪誠醫院、中山大學附屬第一醫院兩家大灣區藥械通政策指定的醫療機構先行使用，後續該產品將在其他藥械通資質醫院陸續引入。 more info >> |
|
| Tuesday, October 22, 2024 |
|
|
Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON Global Phase 3 NefIgArd Clinical Trial |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the "Kidney 360" magazine has published the complete two-year subpopulation data from Chinese patients in the Phase 3 NefIgArd clinical trial of NEFECON under the title "Efficacy and Safety of Nefecon in Patients With Immunoglobulin A Nephropathy From Mainland China: 2-Year NefIgArd Trial Results". more info >> |
|
|
雲頂新耀宣佈耐賦康®NefIgArd III期全球臨床試驗完整中國亞組資料的積極結果 |
| 雲頂新耀（HKEX 1952.HK）是一家專注于創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈《腎臟360》（Kidney 360）雜誌以「Efficacy and Safety of Nefecon in Patients With Immunoglobulin A Nephropathy From Mainland China: 2-Year NefIgArd Trial Results」《耐賦康®在中國大陸IgA腎病患者中的療效和安全性：2年NefIgArd試驗結果》為題，刊登了耐賦康®（布地奈德腸溶膠囊，NEFECON®）在NefIgArd III期研究中完整2年資料的中國亞組資料。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
HKTDC launches GreenBiz HK campaign in Bangkok
Mar 18, 2026 19:30: JST
|
|
|
COSCO SHIPPING Ports Announces 2025 Annual Results
Mar 18, 2026 18:36 HKT/SGT
|
|
|
HKTDC launches GreenBiz HK campaign in Bangkok
Mar 18, 2026 18:30 HKT/SGT
|
|
|
中遠海運港口公佈2025年全年業績
Mar 18, 2026 18:26 HKT/SGT
|
|
|
盈立證券勇奪港交所兩項殊榮 港資科技券商實力有目共睹
Mar 18, 2026 17:48 HKT/SGT
|
|
|
盈立证券勇夺港交所两项殊荣 港资科技券商实力有目共睹
Mar 18, 2026 17:48 HKT/SGT
|
|
|
Sunshine Insurance Delivers 2025 Results: Customer Operation System Continues to Innovate
Mar 18, 2026 17:40 HKT/SGT
|
|
|
中远海运港口公布2025年全年业绩
Mar 18, 2026 17:12 HKT/SGT
|
|
|
The 'New Sunshine Strategy' Gains Tangible Results, Sunshine Insurance Group Delivers a High-quality 2025 Performance Report
Mar 18, 2026 16:54 HKT/SGT
|
|
|
AdsDrama Introduces Short Drama Advertising Platform Amid Growth in Digital Content Monetization
Mar 18, 2026 15:30: JST
|
|
|
AdsDrama Introduces Short Drama Advertising Platform Amid Growth in Digital Content Monetization
Mar 18, 2026 14:30 HKT/SGT
|
|
|
三菱重工、新しい経営方針「ITO」の実践による優秀事例を顕彰
Mar 18, 2026 14:00: JST
|
|
|
MHI Commends Outstanding Examples of Implementing its New Management Policy "ITO"
Mar 18, 2026 13:09 JST
|
|
|
Chuangxin Industries Announces 2025 Annual Results
Mar 18, 2026 09:30 HKT/SGT
|
|
|
創新實業公佈2025年全年業績 收入及利潤穩步增長
Mar 18, 2026 09:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
